AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC.

Subgroup analysis of PFS by demographics and baseline characteristics revealed a favorable trend for arm A and arm B versus arm C in most subgroups, with some exceptions; however, this should be treated with caution because of the small sample sizes ( Supplementary Fig. 2 A and B ).

also in 993 other papers